Compile Data Set for Download or QSAR
Report error Found 192 Enz. Inhib. hit(s) with all data for entry = 10344
TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528682(US11198681, Compound I-9)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528693(US11198681, Compound I-20)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528701(US11198681, Compound I-28)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528703(US11198681, Compound I-30)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528710(US11198681, Compound I-37)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528716(US11198681, Compound I-43)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Mouse)
Padlock Therapeutics

US Patent
LigandPNGBDBM528716(US11198681, Compound I-43)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528719(US11198681, Compound I-46)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528719(US11198681, Compound I-46)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Mouse)
Padlock Therapeutics

US Patent
LigandPNGBDBM528721(US11198681, Compound I-48)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528737(US11198681, Compound I-62)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528739(US11198681, Compound I-64)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528740(US11198681, Compound I-65)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528740(US11198681, Compound I-65)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528744(US11198681, Compound I-69)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528744(US11198681, Compound I-69)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528746(US11198681, Compound I-70)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528746(US11198681, Compound I-70)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528747(US11198681, Compound I-71)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528749(US11198681, Compound I-73)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528754(US11198681, Compound I-78)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528757(US11198681, Compound I-81)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528758(US11198681, Compound I-82)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528760(US11198681, Compound I-84)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528761(US11198681, Compound I-85)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528762(US11198681, Compound I-86)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528764(US11198681, Compound I-87)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528766(US11198681, Compound I-89)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528769(US11198681, Compound I-92)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528778(US11198681, Compound I-102)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528781(US11198681, Compound I-105)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528784(US11198681, Compound I-108)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528786(US11198681, Compound I-111)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528787(US11198681, Compound I-112)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528790(US11198681, Compound I-115)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528791(US11198681, Compound I-117)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528684(US11198681, Compound I-11)
Affinity DataIC50: 3.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528685(US11198681, Compound I-12)
Affinity DataIC50: 3.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528691(US11198681, Compound I-18)
Affinity DataIC50: 3.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Mouse)
Padlock Therapeutics

US Patent
LigandPNGBDBM528692(US11198681, Compound I-19)
Affinity DataIC50: 3.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Mouse)
Padlock Therapeutics

US Patent
LigandPNGBDBM528701(US11198681, Compound I-28)
Affinity DataIC50: 3.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528702(US11198681, Compound I-29)
Affinity DataIC50: 3.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Mouse)
Padlock Therapeutics

US Patent
LigandPNGBDBM528703(US11198681, Compound I-30)
Affinity DataIC50: 3.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528705(US11198681, Compound I-32)
Affinity DataIC50: 3.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Mouse)
Padlock Therapeutics

US Patent
LigandPNGBDBM528710(US11198681, Compound I-37)
Affinity DataIC50: 3.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528711(US11198681, Compound I-38)
Affinity DataIC50: 3.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Mouse)
Padlock Therapeutics

US Patent
LigandPNGBDBM528711(US11198681, Compound I-38)
Affinity DataIC50: 3.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528712(US11198681, Compound I-39)
Affinity DataIC50: 3.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Mouse)
Padlock Therapeutics

US Patent
LigandPNGBDBM528712(US11198681, Compound I-39)
Affinity DataIC50: 3.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM528716(US11198681, Compound I-43)
Affinity DataIC50: 3.00E+3nMAssay Description:Compounds were solubilised in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

Displayed 1 to 50 (of 192 total ) | Next | Last >>
Jump to: